Published: Thu, February 15, 2018
IT | By Lester Massey

CymaBay Therapeutics (NASDAQ:CBAY) Receives Another Recommendation From Wall Street


The company has 44.95 Million shares outstanding and 43.47 Million shares were floated in market. We have $13.82 PT which if reached, will make NASDAQ:CBAY worth $29.48 million more. The company has market cap of $916.37 million. 877,200 shares of the company's stock traded hands, compared to its average volume of 762,857. It also reduced its holding in Ishares Tr (LQD) by 13,298 shares in the quarter, leaving it with 5,765 shares, and cut its stake in Nextera Energy Inc (NYSE:NEE). It has outperformed by 11.98% the S&P500.

Analysts await Cymabay Therapeutics, Inc.

The company's diluted EPS for trailing twelve months was -1.01. After $-0.21 actual earnings per share reported by Cymabay Therapeutics, Inc. for the previous quarter, Wall Street now forecasts -38.10 % EPS growth. The stock increased 1.09% or $1.22 during the last trading session, reaching $113.08. (NASDAQ:CBAY) news were published by: Globenewswire.com which released: "CymaBay Announces Closing of Public Offering of Common Stock, Including Full ..." on February 01, 2018. Academic research has shown that stocks close to their 52 week highs tend to outperform. Of those holders, 56 had increased positions amounting to 16.08 million shares, 15 had decreased positions amounting to 1.1 million shares, and 7 holders have a held position accounting for 14.4 million shares. Its down 0.52, from 1.74 in 2017Q2. 18 funds opened positions while 51 raised stakes. The shares were bought at an average price of $23.60 per share, for a total transaction of $118,000.00. Parkside Finance Bancshares And invested 0.43% in AbbVie Inc. Midwest Inv Management holds 3.52% or 64,691 shares. Janney Montgomery Scott Ltd Liability Corp invested in 0.01% or 19,045 shares. California Pub Employees Retirement Sys holds 17,600 shares or 0% of its portfolio. (NYSE:RSG) or 14,116 shares. Ratan Cap Mngmt L P invested in 32,077 shares or 0.47% of the stock. Wells Fargo & Company MN grew its position in Flexion Therapeutics by 37.4% in the second quarter. City Hldg Co has 0.02% invested in Republic Services, Inc. Alps Advisors owns 0.01% invested in Flexion Therapeutics, Inc. Following the completion of the acquisition, the insider now owns 35,395 shares of the company's stock, valued at $835,322. Eaton Vance Mgmt stated it has 0% in Flexion Therapeutics, Inc. Natl Bank Of America De has invested 0% in Wix.com Ltd. (NASDAQ:WIX).

Since September 12, 2017, it had 0 insider purchases, and 7 sales for $3.30 million activity.

Dafna Capital Management Llc, which manages about $196.24 million and $161.05 million US Long portfolio, decreased its stake in Immunomedics Inc (NASDAQ:IMMU) by 177,249 shares to 460,451 shares, valued at $6.44M in 2017Q3, according to the filing.


How Company Returns Shareholder's Value?

FLXN has been the topic of several recent analyst reports. On Wednesday, February 7 the stock rating was maintained by Morgan Stanley with "Equal-Weight". (NASDAQ:FLXN) rating on Monday, June 12. Oppenheimer has "Buy" rating and $15.0 target. (NASDAQ:CBAY) to report earnings on March, 22. The firm has "Buy" rating given on Tuesday, October 20 by Canaccord Genuity. On Tuesday, August 8 the stock rating was maintained by Barclays Capital with "Overweight". On Friday, September 1 the stock rating was maintained by Stifel Nicolaus with "Buy". Therefore 100% are positive. Cymabay Therapeutics Inc had 20 analyst reports since July 21, 2015 according to SRatingsIntel. H.C. Wainwright maintained it with "Neutral" rating and $2.50 target in Wednesday, January 4 report.

Analysts expect Parsley Energy, Inc. (NASDAQ:CBAY) earned "Buy" rating by Roth Capital on Thursday, January 25. As per Zacks simplified descending rating scale the ABR rank is displayed in the range of 1 to 5 where 1 represents Strong Buy and 5 a Strong Sell. Iguana Healthcare Management Llc acquired 145,000 shares as Cymabay Therapeutics Inc (CBAY)'s stock rose 21.05%. As per Tuesday, July 21, the company rating was initiated by Piper Jaffray. Cymabay Therapeutics, Inc. (NASDAQ:CBAY) has risen 69.26% since February 14, 2017 and is uptrending. (NASDAQ:CBAY) rating on Tuesday, July 21. (NASDAQ:CBAY) on Monday, July 17 with "Buy" rating. However the company's price to cash per share for most recent quarter stands at 2.27. The insider, EMSTER KURT VON, now holds 436,929 shares of CBAY.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Like this: